Travere Therapeutics Inc (NASDAQ: TVTX) kicked off on Tuesday, down -1.44% from the previous trading day ,before settling in for the closing price of $6.96. Over the past 52 weeks, TVTX has traded in a range of $5.25-$22.75.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales growth of Healthcare Sector giant was 3.07%. While this was happening, its average annual earnings per share was recorded -96.83%. With a float of $75.03 million, this company’s outstanding shares have now reached $75.37 million.
Let’s determine the extent of company efficiency that accounts for 380 employees.
Travere Therapeutics Inc (TVTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.41%, while institutional ownership is 113.82%. The most recent insider transaction that took place on Feb 01 ’24, was worth 166,435. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 19,122 shares at a rate of $8.70, taking the stock ownership to the 350,600 shares. Before that another transaction happened on Feb 01 ’24, when Company’s SVP, GC & CORPORATE SECRETARY sold 4,764 for $8.71, making the entire transaction worth $41,495. This insider now owns 76,270 shares in total.
Travere Therapeutics Inc (TVTX) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 12/30/2023, the organization reported -$1.18 earnings per share (EPS), higher than consensus estimate (set at -$1.27) by $0.09. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.82 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -96.83% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Take a look at Travere Therapeutics Inc’s (TVTX) current performance indicators. Last quarter, stock had a quick ratio of 3.41. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 2.63.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.56, a number that is poised to hit -0.94 in the next quarter and is forecasted to reach -1.83 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Looking closely at Travere Therapeutics Inc (NASDAQ: TVTX), its last 5-days average volume was 0.87 million, which is a drop from its year-to-date volume of 1.2 million. As of the previous 9 days, the stock’s Stochastic %D was 21.17%. Additionally, its Average True Range was 0.46.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 27.45%, which indicates a significant increase from 11.93% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 40.36% in the past 14 days, which was lower than the 70.72% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.98, while its 200-day Moving Average is $10.03. However, in the short run, Travere Therapeutics Inc’s stock first resistance to watch stands at $7.14. Second resistance stands at $7.42. The third major resistance level sits at $7.59. If the price goes on to break the first support level at $6.70, it is likely to go to the next support level at $6.53. Should the price break the second support level, the third support level stands at $6.25.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
The company with the Market Capitalisation of 522.05 million has total of 76,109K Shares Outstanding. Its annual sales at the moment are 145,240 K in contrast with the sum of -111,400 K annual income. Company’s last quarter sales were recorded 37,100 K and last quarter income was 150,740 K.
